A*STAR scientists uncover potential drug target to nip cancer in the bud

(Press-News.org) Contact information: Vithya Selvam
vithya_selvam@a-star.edu.sg
656-826-6291
Agency for Science, Technology and Research (A*STAR), Singapore
A*STAR scientists uncover potential drug target to nip cancer in the bud This discovery could eradicate cancers more effectively and prevent relapses 1. Scientists at A*STAR have discovered an enzyme, Wip1 phosphatase, as a potential target to weed out the progression of cancer. Although studies in the past have revealed that this enzyme plays a critical role in regulating the budding of tumours, scientists have for the first time unearthed a mechanism for its mode of action.

2. The research was conducted by Dr Dmitry Bulavin and his team at A*STAR's Institute of Molecular and Cell Biology (IMCB), with their findings published in the 14 October 2013 issue of the prestigious scientific journal, Cancer Cell.

3. The team discovered that Wip1 phosphatase is a key factor that causes point mutations to sprout in human cancers. These types of mutations stem from errors that are made during DNA replication in the body, causing one base-pair in the DNA sequence to be altered.

4. These mutations can cause cancers to take root, or to become resilient to treatment. By using drugs to inhibit the action of Wip1 phosphatase, cancer growth can be stunted and tumours can be cured without developing resistance. This is a ground-breaking finding that sheds light on how mutations in cancer can potentially be wiped out with drugs, allowing cancers to be treated and eliminated effectively, preventing relapses of tumour growth.

5. Dr Dmitry Bulavin said, "Our work on Wip1 phosphatase for over a decade has now revealed several key features of this molecule. Our current findings strongly support the use of an anti-Wip1 drug for cancer treatment in order to reduce a high frequency of mutations in the genome, which is one of the main drivers of tumour relapses."

6. Prof Hong Wan Jin, Executive Director of IMCB, said, "Dmitry has been the pioneering driver in the mechanistic study of Wip1 phosphatase, and this discovery is monumental in providing novel understanding on the role of Wip1 in cancer at the genomic and systems levels. I am confident that his team at IMCB can further their work in cancer research to offer new approaches for potential drugs against this target." ### Notes for Editor: The research findings described in this media release can be found in the 14 October online issue of Cancer Cell, under the title, "Wip1 controls global heterochromatin silencing via ATM/BRCA1-dependent DNA methylation" by Doria Filipponi1, Julius Muller1, Alexander Emelyanov1 and Dmitry V. Bulavin1,# 1 Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673 # Correspondence should be addressed to: Dmitry Bulavin (dvbulavin@imcb.a-star.edu.sg) AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) For media queries and clarifications, please contact:

Vithya Selvam (Ms)
Senior Officer, Corporate Communications
Agency for Science, Technology and Research
Tel: (+65) 6826 6291
Email: vithya_selvam@a-star.edu.sg

About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is the lead agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. A*STAR oversees 14 biomedical sciences and physical sciences and engineering research institutes, and six consortia & centres, located in Biopolis and Fusionopolis as well as their immediate vicinity. A*STAR supports Singapore's key economic clusters by providing intellectual, human and industrial capital to its partners in industry. It also supports extramural research in the universities, and with other local and international partners. For more information about A*STAR, please visit http://www.a-star.edu.sg.

About Institute of Molecular and Cell Biology (IMCB) The Institute of Molecular and Cell Biology (IMCB) was established in 1987 at the National University of Singapore (NUS) before becoming an autonomous research institute (RI) of A*STAR and moving to Biopolis in 2004. IMCB strives to maintain the scientific excellence of PI-driven research and at the same time aims to promote collaborative team-based projects of medical and industrial relevance. Funded primarily by the Biomedical Research Council (BMRC) of A*STAR, IMCB's research activities focus on four major fields: Animal Models of Development and Disease, Cancer Genetics and Therapeutics, Cell Biology in Health and Disease, and Structural Biology and Drug Discovery. For more information about IMCB, please visit http://www.imcb.a-star.edu.sg.